These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 1705879

  • 1. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L, Weidmann E, Mitrou PS.
    Dtsch Med Wochenschr; 1991 Mar 08; 116(10):384-90. PubMed ID: 1705879
    [No Abstract] [Full Text] [Related]

  • 2. Immunotherapeutic approaches for renal cancer.
    Pizza G, de Vinci C, Viza D.
    Folia Biol (Praha); 2002 Mar 08; 48(5):167-81. PubMed ID: 12448765
    [No Abstract] [Full Text] [Related]

  • 3. [Immunotherapy of metastatic renal cell cancer].
    Manseck A, Wirth M.
    Urologe A; 1993 Sep 08; 32(5):360-73. PubMed ID: 7692655
    [Abstract] [Full Text] [Related]

  • 4. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS, deKernion JB.
    Acta Urol Belg; 1996 May 08; 64(2):3-8. PubMed ID: 8701805
    [No Abstract] [Full Text] [Related]

  • 5. Renal cell carcinoma and interleukin-2: what are the endpoints?
    Figlin RA.
    Cancer J Sci Am; 1997 Dec 08; 3 Suppl 1():S68-9. PubMed ID: 9457397
    [No Abstract] [Full Text] [Related]

  • 6. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D.
    Semin Nephrol; 1987 Jun 08; 7(2):152-62. PubMed ID: 2442806
    [No Abstract] [Full Text] [Related]

  • 7. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
    Quesada JR.
    Semin Oncol; 1988 Aug 08; 15(4):396-407. PubMed ID: 2457256
    [No Abstract] [Full Text] [Related]

  • 8. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP.
    Urol Clin North Am; 1993 May 08; 20(2):283-95. PubMed ID: 7684167
    [Abstract] [Full Text] [Related]

  • 9. [Biologic response modifiers in the treatment of solid tumors].
    Tagliaferri F, Lucandri G, Stipa F, Stipa S.
    Recenti Prog Med; 1991 Jun 08; 82(6):352-8. PubMed ID: 1718019
    [Abstract] [Full Text] [Related]

  • 10. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B, Young M, Ho KJ.
    Int J Clin Pract; 2002 Jun 08; 56(1):36-9. PubMed ID: 11831831
    [Abstract] [Full Text] [Related]

  • 11. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M.
    Urologe A; 1991 Mar 08; 30(2):77-80. PubMed ID: 1711729
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF, Rini BI.
    BJU Int; 2007 May 08; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunotherapy of disseminated renal cell carcinoma.
    Javapour N.
    Md Med J; 1989 Nov 08; 38(11):963. PubMed ID: 2586256
    [No Abstract] [Full Text] [Related]

  • 15. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG.
    APMIS Suppl; 1993 Nov 08; 35():1-26. PubMed ID: 8251200
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Renal cell cancer: is immunotherapy dead?
    Wagstaff J.
    Ann Oncol; 2007 Jul 08; 18 Suppl 9():ix94-7. PubMed ID: 17631604
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.